Table 1 pCR cases after neoadjuvant chemoradiation therapy for borderline resectable and locally advanced pancreatic cancer (2005–2020)
Case | Authors | Journal | Year | pCR rate | Assessment | Chemotherapy | Radiation dose | Status Alive/dead |
|---|---|---|---|---|---|---|---|---|
1 | Katz et al | J Am Coll Surg | 2008 | 4/66 (6.1%) | BR | 5-FU or PTX or GEM or Cape | 30 or 50.4 Gy | 2 (NED)/2 (1 DOD, 1 DOA) |
2 | Rajagopalan et al | Radiat Oncol | 2013 | 3/12 (25%) | BR + LA | GEM + Cape or FFN | 36 Gy (SBRT) | NR |
3 | Rose et al | Ann Surg Oncol | 2014 | 3/31 (9.7%) | BR | GD | 50.4 Gy | NR |
4 | Pietrasz et al | Ann Surg Oncol | 2015 | 12/80 (15%) | BR + LA | FFN | 54 Gy | NR |
5 | Hirata et al | Radiother Oncol | 2015 | 6/157 (4%) | BR + LA | GEM | 50 Gy | NR |
6 | Katz et al | JAMA Surg | 2016 | 2/22 (13%) | BR | FFN + Cape | 50.4 Gy | NR |
7 | Chuong et al | J Gastrointest Oncol | 2016 | 4/36 (11.1%) | BR | GTX | 30–40 Gy (SBRT) | 4 (NED)/0 |
8 | Rashid et al | Ann Surg Oncol | 2016 | 10/55 (18.2%) | BR | GTX | 30–40 Gy (SBRT) | NR |
9 | Mellon et al | Acta Oncol | 2017 | 6/81 (7.4%) | BR | GEM or GTX or GnP or FFN or others | 30–50 Gy (SBRT) | 6 (5 NED, 1 AWD; liver)/ 0 |
10 | Hashemi-Sadraei et al | Am J Clin Oncol | 2018 | 5/53 (9.4%) | BR | GEM or GEM + SFB or GEM + ERL or GnP or FFN | 45–54 Gy | 3 (2 NED, 1 AWD; unknown)/2 (1 DOD, 1 DOA) |
11 | Takahashi et al | Pancreas | 2018 | 3/24 (12.5%) | BR | GnP | 60 Gy | NR |
12 | Jang et al | Ann Surg | 2018 | 2/17 (11.8%) | BR | GEM | 54 Gy | NR |
13 | He et al | Ann Surg | 2018 | 19/186 (10.2%) | BR + LA | GnP or GX or FFX | NR (SBRT or conventional) | 8 (NED)/NE; 2 recurrence, 3 liver, 1 lung, 3 multiple |
14 | Blair et al | Surgery | 2018 | 14/168 (8.3%) | BR + LA | 5-FU or GEM or Cape or FFX or others | 33 Gy (SBRT) or 45–54 Gy (CRT) | NR |
15 | Lewis et al | J Gastrointest Oncol | 2019 | 2/30 (6.7%) | BR + LA | GEM | 45–57 Gy (IMRT) | NR |
16 | Neyaz et al | Histopathology | 2020 | 15/92 (16.3%) | BR + LA | FFX | 50.4 Gy | NR |